Raymond James & Associates Reduces Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Raymond James & Associates trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 54.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,920 shares of the medical equipment provider’s stock after selling 16,374 shares during the period. Raymond James & Associates’ holdings in Lantheus were worth $863,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in LNTH. Insight Wealth Strategies LLC lifted its position in Lantheus by 6.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 18,365 shares of the medical equipment provider’s stock worth $1,139,000 after acquiring an additional 1,139 shares in the last quarter. Moody National Bank Trust Division bought a new position in Lantheus in the 4th quarter worth about $928,000. Legacy Wealth Asset Management LLC bought a new stake in Lantheus during the 4th quarter valued at $492,000. FCF Advisors LLC raised its stake in shares of Lantheus by 121.8% during the fourth quarter. FCF Advisors LLC now owns 16,328 shares of the medical equipment provider’s stock valued at $1,012,000 after purchasing an additional 8,966 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its stake in shares of Lantheus by 50.4% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 33,634 shares of the medical equipment provider’s stock worth $2,338,000 after acquiring an additional 11,276 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on LNTH shares. Truist Financial restated a “buy” rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. JMP Securities reiterated a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a research note on Friday, February 23rd. Finally, StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $104.71.

Lantheus Trading Down 1.2 %

Shares of Lantheus stock opened at $63.07 on Tuesday. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average is $60.94 and its 200-day moving average is $62.78. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $100.85. The stock has a market cap of $4.32 billion, a P/E ratio of 13.59 and a beta of 0.54.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping the consensus estimate of $1.33 by $0.26. The business had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. Equities research analysts predict that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 94,545 shares of company stock valued at $6,169,936. 2.10% of the stock is currently owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.